Sinotherapeutics (SH:688247)2022-10-26 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥59,050,376.49, a decrease of 21.29% compared to the same period last year[5] - Net profit attributable to shareholders of the listed company reached ¥23,542,682.47, a slight increase of 0.25% year-on-year[5] - Total operating revenue for the first three quarters of 2022 was CNY 186,903,609.72, a decrease of 19.1% compared to CNY 231,183,695.88 in the same period of 2021[20] - Net profit for the third quarter of 2022 was CNY 67,102,611.35, an increase of 10.4% from CNY 60,989,846.15 in the same quarter of 2021[22] - The company reported a total comprehensive income of CNY 67,293,856.17 for the third quarter of 2022, compared to CNY 60,976,227.94 in the same quarter of 2021[23] Assets and Liabilities - Total assets increased by 50.19% to ¥1,300,375,431.95 compared to the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,300,375,431.95, an increase from RMB 865,805,176.29 at the end of 2021, representing a growth of approximately 50.0%[15] - The company's total liabilities decreased to RMB 150,676,111.78 from RMB 160,617,855.40, a reduction of approximately 6.0%[17] - The equity attributable to shareholders increased to RMB 453,340,000.00 from RMB 408,000,000.00, representing a growth of about 11.1%[17] - The company's equity attributable to shareholders reached CNY 1,149,699,320.17, an increase of 63.1% from CNY 705,187,320.89 in the previous year[18] Cash Flow - The net cash flow from operating activities was ¥53,938,348.13, a decrease of 6.02%[6] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 53,938,348.13, compared to CNY 57,391,877.35 in the same period of 2021, reflecting a decrease of 7.9%[25] - The net cash flow from investing activities was -189,148,252.12, compared to -301,645,870.55 in the previous year, indicating an improvement[26] - Cash inflow from financing activities amounted to 389,930,139.63, while cash outflow was 13,507,380.76, resulting in a net cash flow of 376,422,758.87[26] - The overall cash increase was 245,021,205.94 compared to a decrease of 246,434,472.35 in the previous year[26] Research and Development - Research and development expenses totaled ¥16,116,208.02, down 18.09% from the previous year, representing 27.29% of operating revenue, an increase of 1.07 percentage points[6] - Research and development expenses for the first three quarters of 2022 were CNY 51,411,301.00, down 29.3% from CNY 72,799,581.02 in the previous year[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,077[10] - Major shareholder Shanghai Lianhe Investment holds 51.40% of the shares, totaling 233,000,000 shares[11] Investments - The company has a long-term investment of RMB 63,575,879.73, which increased from RMB 27,416,602.48, indicating a growth of about 132.5%[16] - The company invested 1,083,000,000.00 in cash for investments, an increase from 707,803,178.07 in the previous year[26] - The company reported a total investment cash outflow of 1,172,783,842.79, significantly higher than 718,849,773.97 from the previous year[26] Other Information - The company has not reported any new product developments or market expansion strategies in this quarter[14] - The company did not apply new accounting standards or interpretations for the year 2022[26]